GLP-1s Update

As of October 2, 2024, Tirzepatide was officially removed from the FDA drug shortage list. Following legal action by the Outsourcing Facilities Association (OFA), the FDA confirmed on December 19, 2024, that the shortage was resolved. Consequently, deadlines were set for pharmacies to stop compounding Tirzepatide: February 18, 2025, for 503A pharmacies and March 19, 2025, for 503B pharmacies.

Semaglutide Update

As of Friday, February 21, 2025, the semaglutide shortage has been marked as "Resolved." However, the OFA plans to continue litigation challenging this resolution. Currently, 503A pharmacies are permitted to compound and dispense semaglutide for 60 days (until April 22, 2025), while 503B pharmacies have a 90-day window (until May 22, 2025).

We will continue to provide updates as new information becomes available.

Doctors’ Weight Loss & MedSpa will continue to make compounded GLP-1 Semaglutide available both for At-Home and In-Clinic patients adhering to the above dates.